Birchview Capital, LP
- SEC CIK
- 0001618205
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 71
- +3 vs. Q1 2025
- Portfolio value
- $100.7M
- −$14.5M (−12.6%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXDXAccelerate Diagnostics, Inc | COM | 325,239 | $2.08K | <0.1% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 17,000 | $19.7K | <0.1% | 00.0% | Unchanged | History |
| ALMSAlumis Inc. | COM | 10,000 | $30.0K | <0.1% | 00.0% | Unchanged | History |
| APVOAptevo Therapeutics Inc. | COM NEW | 10,000 | $30.5K | <0.1% | +10,000 | New | History |
| IFRXInflaRx N.V. | COM | 50,000 | $39.5K | <0.1% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 28,800 | $61.6K | 0.1% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 280,000 | $87.1K | 0.1% | +280,000 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 27,985 | $120.6K | 0.1% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 20,000 | $150.6K | 0.1% | 00.0% | Unchanged | History |
| ZBIOZenas BioPharma, Inc. | COM | 16,500 | $159.9K | 0.2% | 00.0% | Unchanged | History |
| FOLDAmicus Therapeutics, Inc. | COM | 28,000 | $160.4K | 0.2% | 00.0% | Unchanged | History |
| GOSSGossamer Bio, Inc. | COM | 138,176 | $170.0K | 0.2% | 00.0% | Unchanged | History |
| NPCENeuroPace Inc | COM | 16,442 | $183.2K | 0.2% | 00.0% | Unchanged | History |
| BBIOBridgeBio Pharma, Inc. | COM | 5,000 | $215.9K | 0.2% | +5,000 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 25,000 | $239.8K | 0.2% | +25,000 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 14,000 | $242.3K | 0.2% | 00.0% | Unchanged | History |
| TXG10x Genomics, Inc. | CL A COM | 22,000 | $254.8K | 0.3% | −28,000−56.0% | Reduced | History |
| WVEWave Life Sciences, Inc. | SHS | 40,300 | $261.9K | 0.3% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 40,000 | $287.2K | 0.3% | +40,000 | New | History |
| TELATELA Bio, Inc. | COM | 155,000 | $300.7K | 0.3% | 00.0% | Unchanged | History |
| CADLCandel Therapeutics, Inc. | COM | 60,000 | $303.6K | 0.3% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 10,000 | $330.4K | 0.3% | 00.0% | Unchanged | History |
| BPMCBlueprint Medicines Corp | COM | 2,700 | $346.1K | 0.3% | 00.0% | Unchanged | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 40,000 | $358.4K | 0.4% | 00.0% | Unchanged | History |
| ATECAlphatec Holdings, Inc. | COM NEW | 33,000 | $366.3K | 0.4% | 00.0% | Unchanged | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 8,000 | $377.6K | 0.4% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 32,110 | $458.2K | 0.5% | 00.0% | Unchanged | History |
| PACBPacific Biosciences of California, Inc. | COM | 400,000 | $496.0K | 0.5% | +400,000 | New | History |
| HALOHalozyme Therapeutics, Inc. | COM | 10,000 | $520.2K | 0.5% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 70,000 | $550.2K | 0.5% | +44,000+169.2% | Added | History |
| IMNMImmunome Inc. | COM | 60,000 | $558.0K | 0.6% | +60,000 | New | History |
| KIDSOrthopediatrics Corp | COM | 26,000 | $558.5K | 0.6% | +6,000+30.0% | Added | History |
| NTLAIntellia Therapeutics, Inc. | COM | 60,000 | $562.8K | 0.6% | +60,000 | New | History |
| SRRKScholar Rock Holding Corp | COM | 16,000 | $566.7K | 0.6% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 134,000 | $570.8K | 0.6% | +134,000 | New | History |
| AXSMAxsome Therapeutics, Inc. | COM | 6,000 | $626.3K | 0.6% | 00.0% | Unchanged | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 18,000 | $654.5K | 0.6% | +2,000+12.5% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 21,000 | $657.3K | 0.7% | 00.0% | Unchanged | History |
| OMOutset Medical, Inc. | COM | 34,584 | $664.4K | 0.7% | +10,000+40.7% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 16,000 | $694.9K | 0.7% | +8,000+100.0% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 36,000 | $746.6K | 0.7% | +36,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 67,000 | $757.4K | 0.8% | −20.0% | Reduced | History |
| FCXFreeport-McMoran Inc | Stock | 18,033 | $781.7K | 0.8% | +18,033 | New | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 30,000 | $830.1K | 0.8% | −60.0% | Reduced | History |
| SLDBSolid Biosciences Inc. | COM NEW | 178,768 | $870.6K | 0.9% | +50,000+38.8% | Added | History |
| TMCITreace Medical Concepts, Inc. | COM | 176,947 | $1.04M | 1.0% | +12,000+7.3% | Added | History |
| DCGODocGo Inc. | COM | 764,062 | $1.20M | 1.2% | −100,000−11.6% | Reduced | History |
| UTHRUnited Therapeutics Corp | COM | 4,250 | $1.22M | 1.2% | −3,250−43.3% | Reduced | History |
| QUREuniQure N.V. | SHS | 98,697 | $1.38M | 1.4% | +10,000+11.3% | Added | History |
| MASIMasimo Corp | COM | 8,280 | $1.39M | 1.4% | −3,000−26.6% | Reduced | History |
| ALKSAlkermes plc. | SHS | 50,000 | $1.43M | 1.4% | 00.0% | Unchanged | History |
| FHTXFoghorn Therapeutics Inc. | COM | 310,930 | $1.46M | 1.5% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 103,000 | $1.52M | 1.5% | −35,000−25.4% | Reduced | History |
| BDSXBiodesix Inc | COM | 5,736,113 | $1.62M | 1.6% | 00.0% | Unchanged | History |
| AXGNAxogen, Inc. | COM | 161,000 | $1.75M | 1.7% | 00.0% | Unchanged | History |
| NVCRNovoCure Ltd | ORD SHS | 101,000 | $1.80M | 1.8% | +70,000+225.8% | Added | History |
| HROWHarrow, Inc. | COM | 60,000 | $1.83M | 1.8% | −12,910−17.7% | Reduced | History |
| EQTEQT Corp | Stock | 34,619 | $2.02M | 2.0% | 00.0% | Unchanged | History |
| QDELQuidelOrtho Corp | COM | 72,548 | $2.09M | 2.1% | +4,929+7.3% | Added | History |
| CSTLCastle Biosciences Inc | COM | 110,600 | $2.26M | 2.2% | +22,196+25.1% | Added | History |
| ELUTElutia Inc. | CL A COM | 1,159,059 | $2.29M | 2.3% | −28,676−2.4% | Reduced | History |
| STOKStoke Therapeutics, Inc. | COM | 210,000 | $2.38M | 2.4% | −50.0% | Reduced | History |
| PTGXProtagonist Therapeutics, Inc | COM | 48,000 | $2.65M | 2.6% | −20.0% | Reduced | History |
| PRTAProthena Corp Public Ltd Co | SHS | 451,019 | $2.74M | 2.7% | +118,045+35.5% | Added | History |
| PHRPhreesia, Inc. | COM | 114,700 | $3.26M | 3.2% | 00.0% | Unchanged | History |
| NBIXNeurocrine Biosciences Inc | Stock | 30,940 | $3.89M | 3.9% | +700+2.3% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 187,800 | $4.05M | 4.0% | −75,600−28.7% | Reduced | History |
| OVVOvintiv Inc. | COM | 107,500 | $4.09M | 4.1% | +55,300+105.9% | Added | History |
| CORTCorcept Therapeutics Inc | COM | 67,200 | $4.93M | 4.9% | +1,200+1.8% | Added | History |
| KLACKLA Corp | COM NEW | 15,848 | $14.2M | 14.1% | +15,848 | New | History |
| BMYBristol Myers Squibb Co | Stock | 323,358 | $15.0M | 14.9% | −361,834−52.8% | Reduced | History |
Sold out since Q1 2025 (9)
Positions held at the end of Q1 2025 that are gone from this filing.
| Security | Class | Shares in Q1 2025 | Value in Q1 2025 | % of portfolio in Q1 2025 | History |
|---|---|---|---|---|---|
| SWTXSpringWorks Therapeutics, Inc. | COM | 8,280 | $365.4K | 0.3% | History |
| LUNGPulmonx Corp | COM | 51,000 | $343.2K | 0.3% | History |
| ARVNArvinas, Inc. | COM | 30,000 | $210.6K | 0.2% | History |
| KROSKeros Therapeutics, Inc. | COM | 15,000 | $152.8K | 0.1% | History |
| LQDALiquidia Corp | COM NEW | 10,013 | $147.7K | 0.1% | History |
| Direxion Shs ETF Tr25459W102 | DLY TECH BULL 3X | 20,000 | $144.4K | 0.1% | – |
| ATRAAtara Biotherapeutics, Inc. | COM NEW | 22,000 | $130.7K | 0.1% | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 15,500 | $76.6K | 0.1% | History |
| CMPXCompass Therapeutics, Inc. | COM | 24,000 | $45.6K | <0.1% | History |